Cidara Therapeutics, Inc. CDTX
Set alert
221.38 USD 0.00 0.00%
As of Jan 8, 9:30 AM ET
221.38 Day range 221.38
94.50 52-week range 221.42
- YTD
- +0.22%
- 1 year
- +725.74%
- Open
- 221.38
- Prev close
- 221.38
- Mkt cap
- 5.61B
- Vol
- 2.69M
- Avg vol
- 919.35K
- EPS
- -11.78
- P/E
- -46.61
- Div yield
- 0.00%
More statistics
- Low
- 221.38
- High
- 221.38
- Beta
- 1.53
- Inst. own
- 103.89%
- Dividend
- 0.00
5Y chart
Events in this range
- Apr 24, 2024Split: 1 for 20
- Aug 13, 2024Earnings: -19.99; estimate -3.94; surprise -407.36%
- Nov 7, 2024Earnings: -2.38; estimate -5.22; surprise 54.41%
- Mar 6, 2025Earnings: -5.38; estimate -5.28; surprise -1.89%
- May 8, 2025Earnings: -1.66; estimate -5.45; surprise 69.54%
- Aug 7, 2025Earnings: -1.65; estimate -1.87; surprise 11.76%
- Oct 21, 2025Rating: HC Wainwright & Co. · Buy → Buy
- Nov 6, 2025Earnings: -3.1; estimate -1.34; surprise -131.34%
- Nov 7, 2025Rating: Needham · Buy → Buy
- Nov 7, 2025Rating: RBC Capital · Outperform → Outperform
- Nov 14, 2025Downgrade: Needham · Buy → Hold
- Nov 14, 2025Downgrade: HC Wainwright & Co. · Buy → Neutral
- Nov 18, 2025Downgrade: Guggenheim · Buy → Neutral
Signals (74)
| Name | Date | Ago |
|---|---|---|
| RSI: Overbought | Jun 23, 2025 | 1 year ago |
| MACD: Buy Signal | Jun 9, 2025 | 1 year ago |
| SMA: Bullish | May 16, 2025 | 1 year ago |
| SMA: Bullish | May 16, 2025 | 1 year ago |
| SMA: Bearish | May 9, 2025 | 1 year ago |
| SMA: Bearish | May 9, 2025 | 1 year ago |
| SMA: Bullish | Apr 25, 2025 | 1 year ago |
| SMA: Bullish | Apr 17, 2025 | 1 year ago |
| SMA: Bearish | Apr 3, 2025 | 1 year ago |
| SMA: Bearish | Mar 27, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 13, 2025 | 1 year ago |
| SMA: Bullish | Feb 27, 2025 | 1 year ago |
| SMA: Bearish | Feb 20, 2025 | 1 year ago |
| SMA: Bullish | Feb 13, 2025 | 1 year ago |
| SMA: Bearish | Jan 30, 2025 | 1 year ago |
| RSI: Overbought | Dec 10, 2024 | 1 year ago |
| RSI: Overbought | Nov 26, 2024 | 1 year ago |
| SMA: Bullish | Nov 5, 2024 | 1 year ago |
| SMA: Bullish | Oct 28, 2024 | 2 years ago |
| MACD: Buy Signal | Oct 21, 2024 | 2 years ago |
| MACD: Sell Signal | Oct 14, 2024 | 2 years ago |
| MACD: Buy Signal | Oct 7, 2024 | 2 years ago |
| MACD: Sell Signal | Sep 30, 2024 | 2 years ago |
| SMA: Bearish | Aug 30, 2024 | 2 years ago |
| SMA: Bullish | Aug 19, 2024 | 2 years ago |
| SMA: Bearish | Aug 5, 2024 | 2 years ago |
| SMA: Bullish | Jul 29, 2024 | 2 years ago |
| MACD: Buy Signal | Jul 29, 2024 | 2 years ago |
| SMA: Bearish | Jul 22, 2024 | 2 years ago |
| SMA: Bullish | Jul 15, 2024 | 2 years ago |
| MACD: Sell Signal | May 3, 2024 | 2 years ago |
| SMA: Bearish | Apr 19, 2024 | 2 years ago |
| SMA: Bearish | Apr 19, 2024 | 2 years ago |
| SMA: Bullish | Mar 21, 2024 | 2 years ago |
| SMA: Bullish | Mar 21, 2024 | 2 years ago |
| MACD: Buy Signal | Feb 15, 2024 | 2 years ago |
| MACD: Sell Signal | Feb 1, 2024 | 2 years ago |
| SMA: Bearish | Jan 18, 2024 | 2 years ago |
| SMA: Bullish | Dec 28, 2023 | 2 years ago |
| MACD: Buy Signal | Dec 28, 2023 | 2 years ago |
| SMA: Bearish | Oct 17, 2023 | 3 years ago |
| SMA: Bullish | Oct 10, 2023 | 3 years ago |
| SMA: Bearish | Oct 3, 2023 | 3 years ago |
| SMA: Bullish | Sep 12, 2023 | 3 years ago |
| SMA: Bearish | Jun 20, 2023 | 3 years ago |
| SMA: Bearish | Jun 20, 2023 | 3 years ago |
| SMA: Bullish | May 16, 2023 | 3 years ago |
| SMA: Bullish | May 9, 2023 | 3 years ago |
| SMA: Bearish | May 2, 2023 | 3 years ago |
| MACD: Sell Signal | Apr 11, 2023 | 3 years ago |
| SMA: Bearish | Mar 28, 2023 | 3 years ago |
| RSI: Overbought | Mar 21, 2023 | 3 years ago |
| RSI: Overbought | Jan 17, 2023 | 3 years ago |
| SMA: Bullish | Dec 27, 2022 | 3 years ago |
| SMA: Bullish | Dec 27, 2022 | 3 years ago |
| MACD: Buy Signal | Dec 27, 2022 | 3 years ago |
| MACD: Sell Signal | Dec 20, 2022 | 3 years ago |
| SMA: Bearish | Dec 6, 2022 | 3 years ago |
| SMA: Bearish | Dec 6, 2022 | 3 years ago |
| SMA: Bullish | Nov 15, 2022 | 3 years ago |
| SMA: Bullish | Nov 15, 2022 | 3 years ago |
| SMA: Bearish | Sep 26, 2022 | 4 years ago |
| SMA: Bearish | Sep 26, 2022 | 4 years ago |
| SMA: Bullish | Sep 19, 2022 | 4 years ago |
| SMA: Bearish | Sep 12, 2022 | 4 years ago |
| SMA: Bullish | Aug 22, 2022 | 4 years ago |
| SMA: Bearish | Aug 8, 2022 | 4 years ago |
| SMA: Bullish | Aug 1, 2022 | 4 years ago |
| SMA: Bullish | Jul 11, 2022 | 4 years ago |
| RSI: Oversold | May 16, 2022 | 4 years ago |
| SMA: Bearish | Apr 25, 2022 | 4 years ago |
| SMA: Bullish | Apr 18, 2022 | 4 years ago |
| SMA: Bearish | Apr 11, 2022 | 4 years ago |
| SMA: Bullish | Mar 28, 2022 | 4 years ago |
Key statistics
- Market cap
- 5.61B
- Enterprise value
- 5.32B
- Trailing P/E
- -46.61
- PEG ratio
- -1.58
- Price / sales
- 0.00
- Price / book
- 8.15
- Beta
- 1.53
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Total cash
- 0
- Total debt
- 0
- Return on equity
- -23.59%
Analyst view
Price target (mean) —
Ratings (0m) 5 5 buy · 0 hold · 0 sell
- Strong buy2
- Buy3
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -1.33.
Financials — quick view
CDTX Revenue — quarterly 0
CDTX Net income — quarterly -83.23M
CDTX EPS — quarterly -3.10
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 6, 2025 | Sep 30, 2025 | -1.34 | -3.10 | -1.76 | -131.34% |
| Aug 7, 2025 | Jun 30, 2025 | -1.87 | -1.65 | +0.22 | +11.76% |
| May 8, 2025 | Mar 31, 2025 | -5.45 | -1.66 | +3.79 | +69.54% |
| Mar 6, 2025 | Dec 31, 2024 | -5.28 | -5.38 | -0.10 | -1.89% |
| Nov 7, 2024 | Sep 30, 2024 | -5.22 | -2.38 | +2.84 | +54.41% |
| Aug 13, 2024 | Jun 30, 2024 | -3.94 | -19.99 | -16.05 | -407.36% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 18, 2025 | Guggenheim | down | Buy | Neutral |
| Nov 14, 2025 | HC Wainwright & Co. | down | Buy | Neutral |
| Nov 14, 2025 | Needham | down | Buy | Hold |
| Nov 7, 2025 | RBC Capital | main | Outperform | Outperform |
| Nov 7, 2025 | Needham | main | Buy | Buy |
| Oct 21, 2025 | HC Wainwright & Co. | reit | Buy | Buy |
About Cidara Therapeutics, Inc.
Cidara Therapeutics, Inc. is a biotechnology company specializing in the creation, advancement, and commercialization of extended-duration anti-infective drugs. Their mission targets the prevention and treatment of infectious diseases and certain cancers within the U.S. Their primary therapeutic candidate, rezafungin acetate, is an innovative echinocandin antifungal designed to combat and avert severe fungal infections such as candidemia and invasive candidiasis, conditions known for their high fatality rates. Additionally, Cidara utilizes its Cloudbreak platform to engineer conjugated therapies aimed at preventing and treating influenza as well as various other viral illnesses, including respiratory syncytial virus (RSV), human immunodeficiency virus (HIV), and SARS-CoV-2, the pathogen behind COVID-19. Originally incorporated in 2012 as K2 Therapeutics, Inc., the company adopted its current name, Cidara Therapeutics, Inc., in July 2014. Its operations are headquartered in San Diego, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- US
- Employees
- 38
- Website
- msd.platform-apps.io
News
- Cidara Therapeutics (NASDAQ:CDTX) Stock Price Passes Above Fifty Day Moving Average – Should You Sell?
- Merck In Talks To Buy Cancer Drug-Maker Revolution Medicines In A $28 To $32 Billion Deal — Stock Soars Overnight
- Merck In Talks To Buy Cancer Drug-Maker Revolution Medicines In A $28 To $32 Billion Deal — Stock Soars Overnight
- 3,187 Shares in Cidara Therapeutics, Inc. $CDTX Bought by ANB Bank
- Cidara Therapeutics, Inc. (NASDAQ:CDTX) Receives Consensus Recommendation of “Hold” from Analysts
- Is Cidara Therapeutics a Buy After HighVista Strategies Initiated a Position in the Stock?
- Cidara Therapeutics, Inc. (NASDAQ:CDTX) Receives Average Rating of “Hold” from Brokerages
- 3 Potential Mid-Cap Biotech Buyout Targets In 2026
- Geode Capital Management LLC Grows Stock Position in Cidara Therapeutics, Inc. $CDTX
- Halper Sadeh LLC Encourages GIFI, MOVE, RMBI, CDTX Shareholders to Contact the Firm to Discuss Their Rights
Your note
Sign in to keep a note on CDTX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| DAVARPANAH NICOLE NEGAR | Officer | Stock Gift | Dec 28, 2025 | 20,886 |
| KARBE FRANK L | Chief Financial Officer | Stock Award(Grant) | Feb 23, 2025 | 57,500 |
| MINEO CHRYSA | Director | Purchase | Jun 2, 2025 | 3,320 |
| RA CAPITAL MANAGEMENT, L.P. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Jun 25, 2025 | 0 |
| SANDISON TAYLOR | Officer | Sale | Sep 10, 2024 | 23,067 |
| SHAH PREETAM | Chief Financial Officer | Stock Award(Grant) | Mar 14, 2024 | 335,960 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| RA Capital Management, LLC | 13.27% | 3,365,523 | 0 | Jun 29, 2025 |
| Bain Capital Life Sciences Investors, LLC | 9.86% | 2,500,680 | 0 | Jun 29, 2025 |
| Point72 Asset Management, L.P. | 6.03% | 1,527,930 | 0 | Jun 29, 2025 |
| Vivo Capital, LLC | 5.17% | 1,311,425 | 0 | Jun 29, 2025 |
| COMMODORE CAPITAL LP | 4.63% | 1,175,000 | 0 | Jun 29, 2025 |
| BlackRock Inc | 4.37% | 1,107,668 | 0 | Jun 29, 2025 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Mkt Idx Inv | 2.34% | 592,283 | 0 | Jul 30, 2025 |
| iShares Russell 2000 ETF | 1.59% | 404,282 | 0 | Aug 30, 2025 |
| abrdn Healthcare Investors | 0.71% | 179,902 | 0 | Aug 30, 2025 |
| Fidelity Small Cap Index | 0.66% | 168,540 | 0 | Jun 29, 2025 |
| Vanguard Institutional Extnd Mkt Idx Tr | 0.63% | 159,673 | 0 | Jul 30, 2025 |
| iShares Russell 2000 Value ETF | 0.58% | 147,778 | 0 | Aug 30, 2025 |